| Atazanavir. | |
| | |
MedLine Citation:
|
PMID: 15353575 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To review the pharmacology, virology, pharmacokinetics, resistance profile, clinical efficacy, safety, and drug interactions of atazanavir. DATA SOURCES: A PubMed and NLMGateway search (1966-June 2004) utilizing the key words atazanavir and BMS-232632 was performed. Abstracts from scientific meetings, including the Conference on Retroviruses and Opportunistic Infections, International AIDS Society Conference on HIV Pathogenesis and Treatment, Interscience Conference on Antimicrobial Agents and Chemotherapy, and the Infectious Diseases Society of America, were also reviewed. STUDY SELECTION AND DATA EXTRACTION: All publications and meeting abstracts were reviewed, and information relevant to the formulary decision-making process was selected. DATA SYNTHESIS: Atazanavir is a once-daily protease inhibitor (PI) that received approval by the Food and Drug Administration in June 2003. In clinical trials in antiretroviral (ARV)-naïve patients, atazanavir had efficacy similar to that of efavirenz or nelfinavir. In ARV-experienced patients, atazanavir was inferior to lopinavir/ritonavir unless atazanavir was coadministered with low-dose ritonavir. Following failure of an atazanavir-containing regimen in ARV-naïve patients, a unique 150L mutation was seen. Atazanavir resistance is likely when resistance to >/=3 PIs is present. Atazanavir can cause increases in unconjugated bilirubin levels, which rarely leads to jaundice or scleral icterus. In contrast to comparators, atazanavir did not negatively impact the lipid profile. Similar to other PIs, atazanavir is metabolized by and inhibits CYP3A at clinically relevant concentrations; therefore, many potential drug interactions exist. CONCLUSIONS: Atazanavir is a once-daily PI that, unlike other PIs, does not negatively impact the lipid profile. Atazanavir may be particularly desirable in patients with hyperlipidemia or other coronary artery disease risk factors. |
| | |
Authors:
|
Joanne J Orrick; Corklin R Steinhart |
Related Documents
:
|
17953775 - Modelling the evolution of drug resistance in the presence of antiviral drugs. 16527535 - Non-infectious fluorimetric assay for phenotyping of drug-resistant hiv proteinase muta... 11964525 - The human 26s proteasome is a target of antiretroviral agents. 20729545 - Antiretroviral release from poly(dl-lactide-co-glycolide) nanoparticles in mice. 19200025 - Drug resistance in plasmodium: natural products in the fight against malaria. 17098405 - Anthranoid laxatives influence the absorption of poorly permeable drugs in human intest... |
Publication Detail:
|
Type: In Vitro; Journal Article; Review Date: 2004-09-07 |
Journal Detail:
|
Title: The Annals of pharmacotherapy Volume: 38 ISSN: 1060-0280 ISO Abbreviation: Ann Pharmacother Publication Date: 2004 Oct |
Date Detail:
|
Created Date: 2004-09-17 Completed Date: 2004-12-22 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9203131 Medline TA: Ann Pharmacother Country: United States |
Other Details:
|
Languages: eng Pagination: 1664-74 Citation Subset: IM |
Affiliation:
|
Colleges of Nursing and Pharmacy, University of Florida, Gainesville, FL, USA. orricjj@ufl.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Clinical Trials as Topic Drug Interactions Drug Resistance, Viral HIV Infections / drug therapy, virology HIV Protease Inhibitors* / adverse effects, pharmacokinetics, therapeutic use Humans Oligopeptides* / adverse effects, pharmacokinetics, therapeutic use Pyridines* / adverse effects, pharmacokinetics, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/HIV Protease Inhibitors; 0/Oligopeptides; 0/Pyridines; 198904-31-3/atazanavir |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus.
Next Document: Evaluation of lamotrigine toxicity reported to poison centers.